Skip to main content

. 1953 Jun 13;1(4823):1311–1313. doi: 10.1136/bmj.1.4823.1311

Toxic Effects of Phenylbutazone

PMCID: PMC2016584 PMID: 13042232

1311

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

CUDKOWICZ L., JACOBS J. H. Phenylbutazone (butazolidine) in the treatment of chronic arthritis. Lancet. 1953 Jan 31;1(6753):223–224. doi: 10.1016/s0140-6736(53)90891-5. [DOI] [PubMed] [Google Scholar]
DAVIES H. R., BARTER R. W., GEE A., HIRSON C. Observations on the use of butazolidin in arthritis. Br Med J. 1952 Dec 27;2(4799):1392–1394. [PMC free article] [PubMed] [Google Scholar]
HINZ C., LAMONT-HAVERS R. W., COMINSKY B., GAINES L. M. Agranulocytosis following use of phenylbutazone (butazolidin); report of a case. J Am Med Assoc. 1953 Jan 3;151(1):38–39. doi: 10.1001/jama.1953.02940010040009. [DOI] [PubMed] [Google Scholar]
KUZELL W. C., SCHAFFARZICK R. W. Phenylbutazone (butazolidin). Bull Rheum Dis. 1952 Nov;3(3):23–24. [PubMed] [Google Scholar]
STEPHENS C. A. L., Jr, YEOMAN E. E., HOLBROOK W. P., HILL D. F., GOODIN W. L. Benefits and toxicity of phenylbutazone (butazolidin) in rheumatoid arthritis. J Am Med Assoc. 1952 Nov 15;150(11):1084–1086. doi: 10.1001/jama.1952.03680110024007. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES